Sarah Katz Caffeine Safety Act

This bill aims to make caffeine information clearer and help protect people at higher risk of harm. Chain restaurants would have to put a clear “High caffeine” warning next to the name of any standard or temporary menu item that has added caffeine and at least 150 mg per serving, including on drive‑through boards. Packaged foods and dietary supplements with more than 10 mg of caffeine would have to list how many milligrams they contain, say if the caffeine is natural or added, and include an advisory that healthy adults should limit caffeine to about 400 mg a day.

The bill also directs federal health agencies to review caffeine safety, look closely at risks to vulnerable groups, run a public education campaign, and study how caffeinated drinks are marketed, especially to kids and teens .

• Who is affected:

  • Chain restaurants with 20 or more locations must add “High caffeine” labels for qualifying items; “temporary” items are those on the menu fewer than 60 days a year.
  • Food and supplement makers must add caffeine details to labels if the product has more than 10 mg of caffeine.
  • Vulnerable groups considered include children and teens; people with heart issues, seizure disorders, or certain mental health conditions; pregnant or breast‑feeding women; and people sensitive to caffeine.

• What changes:

  • FDA will review how safe caffeine and similar stimulants are in foods and supplements (including guarana and taurine) and report within 6 months; HHS will then decide if caffeine is generally safe for healthy adults .
  • NIH will review caffeine’s effects on vulnerable groups and report within 6 months.
  • HHS, FDA, and CDC will run a public education campaign on safe caffeine use and risks, with special attention to kids and at‑risk groups.
  • GAO will study how caffeinated drinks are marketed in restaurants, stores, and online (including by influencers) and report within 180 days of enactment.

• Funding:

  • Authorizes $1,000,000 for the FDA review and $1,000,000 for the NIH review.